It was reported that larotrectinib (receptor tyrosine kinases [RTK] inhibitor of NTRK fusion) in gastrointestinal (GI) cancer confirmed its response and ability of disease control in heavily pretreated GI patients (7 MSI-H and 1 microsatellite stable tumors [MSS] CRC patients), and demonstrated 4 of 8 CRC patients achieved partial response (11). This evidence concerns the gene NTRK1 and colorectal carcinoma.